It acts on the principle of point destruction of pathogenic proteins. 

The Sistema-BioTech company from the Moscow specialized complex Mosmedpark has made a serious breakthrough in creating an effective and safe drug treatment for diseases such as cancer and atherosclerosis. Specialists of the enterprise, which is engaged in developments in the field of molecular biology, genetics and cellular technologies, patent a new type of targeted therapy, called the Forced Protein Association. 

Treatment without harm to healthy cells 

The term "targeted therapy" in medicine is used to refer to the targeted treatment of malignant tumors. This method is considered more effective and sparing for the body than, for example, chemotherapy, when healthy cells can also suffer during the destruction of cancer cells. 

Scientists from the specialized complex "Mosmedpark" have developed a method for obtaining molecules that can detect and specifically destroy pathological proteins involved in the development of cancer and atherosclerosis. Molecules have already confirmed their effectiveness in experiments on cells, now experts have begun testing them on animals. 

“Our technology is based on the principle of forced interaction of a pathological protein with cellular structures necessary for its natural degradation — lysosomes. The molecules developed using the technology actually act as a bridge directing the pathological protein into lysosomes for its destruction,” said Artem Sirazutdinov, General Director of Sistema-BioTech. 

With this technology, the company obtained two molecules. And if one transports the protein into lysosomes, due to which the effect of slowing down the growth of tumor cells is achieved, the second purifies the blood plasma from the protein responsible for the development of atherosclerosis. Such a molecule directs the pathological protein to the liver cells, where it is destroyed in lysosomes according to the same principle. 

The creation of molecules for protein degradation is the latest trend in pharmacology. Scientists from many countries, including representatives of the largest Swiss pharmaceutical companies, are actively engaged in research in this area. It took Russian specialists from Mosmedpark four years to create the development. According to them, the new technology is designed to radically change the approach to the treatment of cancer and a number of other serious diseases: with its help, it will be possible to create drug molecules for the targeted destruction of almost any membrane or extracellular protein. 

Healthcare Innovation 

The Mosmedpark resident company was founded in 2017. Already at the end of 2020, it brought six scientific and practical developments to the Russian market, including test systems for the early diagnosis of a new coronavirus infection. To date, the enterprise has nine advanced projects. 

On the territory of "Mosmedpark" there is a scientific laboratory of the company with an area of more than a thousand square meters. The production site is located in the Kaluga region. The company is also a member of the International Medical Cluster in Skolkovo. 

Mosmedpark is a specialized complex in the southeast of Moscow, which is managed by the Strogino technopark. 

“The unique infrastructure of Mosmedpark is adapted for research and development in the field of medicine. For example, residents of the site can go through all the necessary procedures and tests related to the preparation for registration of medical devices or medicines in one window mode. This allows innovators to create unique technologies, including those for the treatment of particularly complex and dangerous diseases. In total, Mosmedpark residents have developed more than 50 innovative solutions for the healthcare system,” said Alexei Fursin, Head of the Department of Entrepreneurship and Innovative Development of the City of Moscow. 

In addition to the creation and production of medical devices, equipment and medicines, the residents of Mosmedpark specialize in instrumentation and information technology.